Get notified when VTRS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Pfizer Opioid-Indemnity Dispute (new) — Pfizer requested payment under a provision requiring Viatris to pay 57% of opioid-related losses since July 2019; Viatris disputes the claim, with potential adverse impact if resolved against the company.
NASDAQ: VTRS Viatris Inc 10-Q

Viatris Q2 revenue +4.9% to $3.76B, but net loss widens 2483% on below-the-line costs

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

  • high

    Net loss widened to -$118.8M (-$0.10/share) from -$4.6M prior year, while operating income fell 97% to $6.3M. The bottom-line deterioration did not come from operations—net income remained below operating income, indicating higher below-the-line deductions (taxes, interest, non-operating items), though the filing does not disclose the specific driver.

    MD&A: Earnings Quality verify on EDGAR →
  • high

    Operating income collapsed 97% to $6.3M (from $233.0M) on $177.8M Tyrvaya® impairment, $86.8M Nashik fire charges, and $105.2M restructuring costs.

    MD&A: Operating Income & Nashik verify on EDGAR →
  • high

    Total charges expected: $700-850M over three years. $105.2M recorded in H1 2026.

    MD&A: 2026 Restructuring Program verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (COTY 10-K) is open in full — no account needed.

Partner

Trade VTRS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 26, 2026 · How we verify